T-Knife Therapeutics

Executive Summary

T-Knife Therapeutics is a German biopharmaceutical company pioneering TCR-T cell therapies for solid tumors. Founded in 2018, the company leverages a proprietary fully human TCR discovery platform and synthetic biology to engineer “supercharged” T cells capable of overcoming the immunosuppressive tumor microenvironment. Its lead program targets PRAME, a cancer-testis antigen overexpressed in multiple solid tumors, and is currently in Phase 1 clinical development. T-Knife’s approach aims to generate transformative responses in patients who have limited treatment options, addressing a significant unmet need in oncology. The company has raised venture capital from specialized life science investors and is advancing its pipeline toward proof-of-concept data. With a strong scientific foundation and focus on TCR-T technology, T-Knife is positioned as a potential leader in the cell therapy space, though it remains at an early clinical stage.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim safety and efficacy data readout for lead PRAME-targeted TCR-T therapy35% success
• Q2 2026Presentation of preclinical data for second-generation TCR-T program at major oncology conference (e.g., ASCO or ESMO)70% success
• H2 2026Potential strategic partnership or licensing deal for TCR discovery platform40% success